Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol

INTRODUCTION: Genetic alterations of KIT gene are known to be one of the major causes of melanoma. Those are more common in the mucous and acral subtypes and KIT is regarded as major oncogene in Asian melanomas, where the prevalence of these subtypes is high. Up to date, several clinical trials have...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirai, Ikuko, Tanese, Keiji, Fukuda, Keitaro, Fusumae, Takayuki, Nakamura, Yoshio, Sato, Yasunori, Amagai, Masayuki, Funakoshi, Takeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663894/
https://www.ncbi.nlm.nih.gov/pubmed/34889232
http://dx.doi.org/10.1097/MD.0000000000027832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663894/
https://www.ncbi.nlm.nih.gov/pubmed/34889232
http://dx.doi.org/10.1097/MD.0000000000027832

Ejemplares similares